Navigation Links
Ohr Pharmaceutical and CSHL joint venture to develop trodusquemine, related analogs

NEW YORK, New York On March 3, 2014, Ohr Pharmaceutical (NasdaqCM: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, and leading global cancer research center Cold Spring Harbor Laboratory (CSHL) today announced the establishment of DepYmed Inc., a new joint venture to develop trodusquemine and related analogs.

The new joint venture will be a private entity, initially with equal ownership by Ohr and Cold Spring Harbor Laboratory. The two partners will seek funding and contribute to the research and development of trodusquemine and also newly patented analogs. The goal is to take the program into the clinic and to demonstrate proof of concept. Various options to fund later stage clinical trials will be explored. The continued preclinical research will be conducted under the guidance of Dr. Nicholas Tonks at CSHL.

"Cold Spring Harbor Laboratory is a world class research center that has a track record of establishing successful commercial ventures in the biopharma space," said Irach Taraporewala, President and Chief Executive Officer of Ohr. "We are very pleased to be working with Dr. Nicholas Tonks who is one of the leading authorities on the protein tyrosine phosphatase (PTP) family of enzymes. Dr. Tonks discovered PTP1B, the primary target for trodusquemine. Setting up this joint venture is the optimal way to create shareholder value from this exciting asset and enable it to obtain the appropriate resources. At the same time, Ohr remains focused on the execution of our core strategy to develop novel ophthalmology products."

"At CSHL we strive to bring the benefits of biological research to society," said Teri Willey, Vice President for Business Development and Technology Transfer at CSHL. "We hope that our involvement in this joint venture leads to new therapies that will benefit patients."

The enzyme protein tyrosine phosphatase 1B (PTB1B) is a well-characterized target for a range of therapy areas. Despite its extensive validation, PTP1B has been a challenging target for therapeutic development due to the chemical properties of the enzyme at its active site. Novel approaches are required to exploit this important target fully. In one such approach, we have identified Trodusquemine as a selective, allosteric inhibitor of PTP1B that exerts its effects outside the active site of the enzyme. Trodusquemine has also been shown to cross the blood brain barrier, which enhances its potential applications, and has been well tolerated in dose escalation and dose ranging clinical studies completed to date in over 65 patients. Analogs of Trodusquemine have been identified that are potent inhibitors of PTP1B and have potential delivery route advantages.


Contact: Press Office
Cold Spring Harbor Laboratory

Michael Rice
LifeSci Advisors, LLC

Press Office
Ohr Pharmaceutical Inc.

Related biology news :

1. Faster testing of new pharmaceuticals
2. Inovio Pharmaceuticals CEO Receives 2013 Drug Discovery & Achievement Award
3. Profil Institute Appoints Dan Bradbury, former Amylin Pharmaceutical CEO, to Board of Directors
4. Scripps Research announces research & license agreement with Janssen Pharmaceuticals
5. Ben-Gurion U. researchers and Teva Pharmaceutical Industries Ltd. develop psoriasis drug
6. Scripps Research and Takeda Pharmaceuticals announce expanded research collaboration
7. Sanford-Burnham and 60° Pharmaceuticals to pursue promising target for the treatment of dengue fever
8. Combination of two pharmaceuticals proves effective in the treatment of multiple sclerosis
9. How to Differentiate Your Pharmaceutical Product in the Personalized Medicine Segment
10. Global Biotech and Pharmaceutical Conference Early Bird Registration Discounts End This Week
11. Conatus Pharmaceuticals Appoints Mark F. Morris as Head of Biostatistics
Post Your Comments:
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
(Date:3/22/2016)... , PROVO and ... -- Newborn Screening Ontario (NSO), which operates the highest ... for molecular testing, and Tute Genomics and UNIConnect, leaders ... technology respectively, today announced the launch of a project ... sequencing (NGS) testing panel. NSO has ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... advised by its major shareholders, Clean Technology Fund I, ... United States based venture capital funds which ... Biorem (on a fully diluted, as converted basis), that ... of their entire equity holdings in Biorem to TUS ...
(Date:6/27/2016)... ... ... Parallel 6 , the leading software as a service (SaaS) provider ... Patient Encounter CONSULT module which enables both audio and video telemedicine communication between the ... the CONSULT module, patients and physicians can schedule a face to face virtual patient ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
Breaking Biology Technology: